Genprex Granted Patent for Reqorsa Gene Therapy in Cancer Treatment
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 5 days ago
0mins
Should l Buy GNPX?
Genprex announced that The Israel Patent Office has granted Genprex a patent covering the use of Reqorsa Gene Therapy in combination with PD-1 antibodies for the treatment of cancer. This patent will expand on the previously granted patents for REQORSA in combination with PD-1 antibodies, which have been granted in the U.S., Japan, Mexico, Russia, Australia, Chile, China, Singapore and Europe.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy GNPX?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on GNPX
About GNPX
Genprex, Inc. is a clinical-stage gene therapy company focused on developing therapies for patients with cancer and diabetes. The Company's technologies are designed to administer disease-fighting genes to provide new therapies for large patient populations with cancer and diabetes, who have limited treatment options. Its oncology program utilizes its systemic, non-viral Oncoprex Delivery System, which uses lipid-based nanoparticles in a lipoplex form to deliver tumor suppressor gene-expressing plasmids to cancer cells. Its oncology drug candidate, Reqorsa Gene Therapy (quaratusugene ozeplasmid), is developed in combination with approved cancer drugs to treat Non-Small Cell Lung Cancer (NSCLC) and Small Cell Lung Cancer (SCLC). GPX-002 is being developed by the Company using the same construct for the treatment of both Type 1 diabetes and Type 2 diabetes. GPX-002 for Type 1 diabetes is designed to work by transforming alpha cells in the pancreas into functional beta-like cells.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
GENPREX AWARDED PATENT BY ISRAEL PATENT OFFICE FOR COMBINING REQORSA® GENE THERAPY WITH PD-1 ANTIBODIES IN CANCER TREATMENT
Patent Grant: GENPREX has received a patent grant from the Israel Patent Office for its combination therapy involving REQORSA® gene therapy and PD-1 antibodies.
Cancer Treatment: The patented combination is aimed at treating cancer, highlighting GENPREX's innovative approach in oncology.
See More
Genprex Partners with UT MD Anderson to Research Lung Cancer Biomarkers
- Research Agreement Signed: Genprex has entered into a new Sponsored Research Agreement with The University of Texas MD Anderson Cancer Center to study biomarkers that may predict patient response to Reqorsa gene therapy, demonstrating the company's commitment to personalized cancer treatment.
- Biomarker Discovery: Researchers have identified TROP2 and PTEN as potential biomarkers in preclinical studies, which may increase the likelihood of patient response to Reqorsa, thereby optimizing patient selection strategies for clinical trials.
- Clinical Trial Progress: The Acclaim-1 and Acclaim-3 clinical trials are currently underway, with the former combining Reqorsa with AstraZeneca's Tagrisso and the latter with Genentech's Tecentriq, both showing good tolerability and early signs of efficacy.
- Long-term Treatment Effects: In the Acclaim-1 trial, one patient experienced over 42 months of progression-free survival following Reqorsa treatment, indicating that this therapeutic approach may offer significant long-term benefits for certain patients.
See More
Genprex Unveils Positive Data on Reqorsa Gene Therapy for Lung Cancer
- Preclinical Data Presentation: Genprex will present positive preclinical data on its lead drug candidate, Reqorsa, at the 2026 AACR Annual Meeting, indicating its multifaceted potential in treating non-small cell lung cancer, which could provide new therapeutic options for patients.
- Biomarker Discovery: Researchers identified TROP2 and PTEN as potential biomarkers for response to TUSC2 gene therapy, a finding that could refine patient selection strategies and enhance the therapeutic efficacy of Reqorsa, holding significant clinical application value.
- Enhanced Antitumor Activity: In mouse models, the combination of Quar Oze with other drugs resulted in a 79% tumor shrinkage, demonstrating its potential as an adjunct therapy, particularly for patients with resistance, which is crucial for advancing treatment options.
- Immune Enhancement Effects: The restoration of TUSC2 significantly boosted natural killer cell cytotoxicity, indicating that Reqorsa not only targets tumor cells directly but also activates the immune system, supporting its development as a dual-function therapeutic approach.
See More
Genprex to Participate in BIO Europe Spring Conference
- Executive Attendance: Genprex's CEO Ryan Confer and Senior VP of Intellectual Property Thomas Gallagher will attend the BIO Europe Spring conference in Lisbon from March 23-25, 2026, showcasing the company's advancements in gene therapies for cancer and diabetes to attract potential investors and partners.
- One-on-One Meeting Opportunities: Throughout the conference, Genprex executives will conduct one-on-one meetings with industry groups to provide an overview of the company's gene therapies, with over 3,700 executives from biotech, pharma, and finance expected to participate, fostering business development and collaboration opportunities.
- Clinical Trial Progress: Genprex's lead product candidate, Reqorsa® gene therapy, is currently undergoing two clinical trials for NSCLC and SCLC, both of which have received FDA Fast Track Designation, indicating the company's potential and competitiveness in the cancer treatment market.
- Diabetes Treatment Innovation: Genprex's diabetes gene therapy GPX-002 delivers Pdx1 and MafA genes directly to the pancreas through a novel infusion process, aiming to transform pancreatic alpha cells into functional beta-like cells, potentially offering new treatment options for diabetes patients and enhancing the company's position in the diabetes treatment market.
See More
Congressional Trading Activity Insights
- Small-Cap Focus: Congressman Tim Moore has made multiple trades in 2025, including purchasing shares of Genprex, a gene therapy company with a market cap of $5.2 million, indicating a continued interest in small-cap stocks that may influence investor confidence in this sector.
- Significant Trade Amounts: Moore's three purchases of Genprex totaled between $31,000 and $115,000, reflecting his optimism about the company despite its recent poor performance, which could attract the attention of other investors.
- Investment in Simply Good Foods: Moore also bought shares of Simply Good Foods, with investments ranging from $30,000 to $100,000, despite the company's stock price dropping 53% over the past 52 weeks, highlighting the potential for high-risk investments.
- Outstanding Trading Performance: Moore was recognized as the top-performing member of Congress for stock trades in 2025, achieving a 52% return that significantly outperformed the S&P 500's 16.6% gain, which may draw more investors to his trading strategies.
See More
Growth Prospects for the EGFR-NSCLC Market Analyzed
- Market Size Forecast: The EGFR-NSCLC market is projected to reach $6 billion by 2024, with the U.S. accounting for approximately 56% of the total market, indicating strong demand for new therapies and significant economic potential in this region.
- Rising Patient Numbers: In 2024, nearly 117,000 new cases of EGFR-NSCLC are expected, and as testing rates increase, more patients with EGFR mutations are identified, driving the demand for targeted therapies and signaling ongoing market expansion.
- Active Drug Development: Several new drugs, including Zipalertinib and Firmonertinib, are in clinical trials and are anticipated to introduce new treatment options, which not only diversify the therapeutic landscape but also have the potential to redefine existing treatment standards and improve patient survival rates.
- Evolving Competitive Landscape: The convergence of TKIs, ADCs, and gene therapies is intensifying competition in the EGFR-NSCLC market, where future winners will depend on efficacy, resistance coverage, and combination therapy potential, driving innovation and growth in the industry.
See More
GENPREX AWARDED PATENT BY ISRAEL PATENT OFFICE FOR COMBINING REQORSA® GENE THERAPY WITH PD-1 ANTIBODIES IN CANCER TREATMENT
Patent Grant: GENPREX has received a patent grant from the Israel Patent Office for its combination therapy involving REQORSA® gene therapy and PD-1 antibodies.
Cancer Treatment: The patented combination is aimed at treating cancer, highlighting GENPREX's innovative approach in oncology.
See More
Genprex Partners with UT MD Anderson to Research Lung Cancer Biomarkers
- Research Agreement Signed: Genprex has entered into a new Sponsored Research Agreement with The University of Texas MD Anderson Cancer Center to study biomarkers that may predict patient response to Reqorsa gene therapy, demonstrating the company's commitment to personalized cancer treatment.
- Biomarker Discovery: Researchers have identified TROP2 and PTEN as potential biomarkers in preclinical studies, which may increase the likelihood of patient response to Reqorsa, thereby optimizing patient selection strategies for clinical trials.
- Clinical Trial Progress: The Acclaim-1 and Acclaim-3 clinical trials are currently underway, with the former combining Reqorsa with AstraZeneca's Tagrisso and the latter with Genentech's Tecentriq, both showing good tolerability and early signs of efficacy.
- Long-term Treatment Effects: In the Acclaim-1 trial, one patient experienced over 42 months of progression-free survival following Reqorsa treatment, indicating that this therapeutic approach may offer significant long-term benefits for certain patients.
See More
Genprex Unveils Positive Data on Reqorsa Gene Therapy for Lung Cancer
- Preclinical Data Presentation: Genprex will present positive preclinical data on its lead drug candidate, Reqorsa, at the 2026 AACR Annual Meeting, indicating its multifaceted potential in treating non-small cell lung cancer, which could provide new therapeutic options for patients.
- Biomarker Discovery: Researchers identified TROP2 and PTEN as potential biomarkers for response to TUSC2 gene therapy, a finding that could refine patient selection strategies and enhance the therapeutic efficacy of Reqorsa, holding significant clinical application value.
- Enhanced Antitumor Activity: In mouse models, the combination of Quar Oze with other drugs resulted in a 79% tumor shrinkage, demonstrating its potential as an adjunct therapy, particularly for patients with resistance, which is crucial for advancing treatment options.
- Immune Enhancement Effects: The restoration of TUSC2 significantly boosted natural killer cell cytotoxicity, indicating that Reqorsa not only targets tumor cells directly but also activates the immune system, supporting its development as a dual-function therapeutic approach.
See More
Genprex to Participate in BIO Europe Spring Conference
- Executive Attendance: Genprex's CEO Ryan Confer and Senior VP of Intellectual Property Thomas Gallagher will attend the BIO Europe Spring conference in Lisbon from March 23-25, 2026, showcasing the company's advancements in gene therapies for cancer and diabetes to attract potential investors and partners.
- One-on-One Meeting Opportunities: Throughout the conference, Genprex executives will conduct one-on-one meetings with industry groups to provide an overview of the company's gene therapies, with over 3,700 executives from biotech, pharma, and finance expected to participate, fostering business development and collaboration opportunities.
- Clinical Trial Progress: Genprex's lead product candidate, Reqorsa® gene therapy, is currently undergoing two clinical trials for NSCLC and SCLC, both of which have received FDA Fast Track Designation, indicating the company's potential and competitiveness in the cancer treatment market.
- Diabetes Treatment Innovation: Genprex's diabetes gene therapy GPX-002 delivers Pdx1 and MafA genes directly to the pancreas through a novel infusion process, aiming to transform pancreatic alpha cells into functional beta-like cells, potentially offering new treatment options for diabetes patients and enhancing the company's position in the diabetes treatment market.
See More
Congressional Trading Activity Insights
- Small-Cap Focus: Congressman Tim Moore has made multiple trades in 2025, including purchasing shares of Genprex, a gene therapy company with a market cap of $5.2 million, indicating a continued interest in small-cap stocks that may influence investor confidence in this sector.
- Significant Trade Amounts: Moore's three purchases of Genprex totaled between $31,000 and $115,000, reflecting his optimism about the company despite its recent poor performance, which could attract the attention of other investors.
- Investment in Simply Good Foods: Moore also bought shares of Simply Good Foods, with investments ranging from $30,000 to $100,000, despite the company's stock price dropping 53% over the past 52 weeks, highlighting the potential for high-risk investments.
- Outstanding Trading Performance: Moore was recognized as the top-performing member of Congress for stock trades in 2025, achieving a 52% return that significantly outperformed the S&P 500's 16.6% gain, which may draw more investors to his trading strategies.
See More
Growth Prospects for the EGFR-NSCLC Market Analyzed
- Market Size Forecast: The EGFR-NSCLC market is projected to reach $6 billion by 2024, with the U.S. accounting for approximately 56% of the total market, indicating strong demand for new therapies and significant economic potential in this region.
- Rising Patient Numbers: In 2024, nearly 117,000 new cases of EGFR-NSCLC are expected, and as testing rates increase, more patients with EGFR mutations are identified, driving the demand for targeted therapies and signaling ongoing market expansion.
- Active Drug Development: Several new drugs, including Zipalertinib and Firmonertinib, are in clinical trials and are anticipated to introduce new treatment options, which not only diversify the therapeutic landscape but also have the potential to redefine existing treatment standards and improve patient survival rates.
- Evolving Competitive Landscape: The convergence of TKIs, ADCs, and gene therapies is intensifying competition in the EGFR-NSCLC market, where future winners will depend on efficacy, resistance coverage, and combination therapy potential, driving innovation and growth in the industry.
See More
